Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amgevita in moderate to severe inflammatory bowel disease
2019-003662-40Phase 4Terminated
- Sponsor
- Universitätsklinikum Erlangen
- Start
- Oct 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of adalimumab in inflammatory bowel disease (IBD), Crohn's disease and autoimmune colitis, sponsored by Universitätsklinikum Erlangen. Primary endpoint: Clinical response at 13 ± 1 weeks. Started Oct 2019; status: terminated.
02
Drugs
03
Conditions
inflammatory bowel disease (IBD)Crohn's diseaseautoimmune colitis
Beyond the preview
Go deeper on 2019-003662-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003662-40.